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Abstract
Background: Type 2 diabetes develops due to a combination of insulin resistance and b-cell failure and current therapeutics
aim at both of these underlying causes. Several negative regulators of insulin signaling are known and are the subject of
drug discovery efforts. We sought to identify novel contributors to insulin resistance and hence potentially novel targets for
therapeutic intervention.
Methodology: An arrayed cDNA library encoding 18,441 human transcripts was screened for inhibitors of insulin signaling
and revealed known inhibitors and numerous potential novel regulators. The novel hits included proteins of various
functional classes such as kinases, phosphatases, transcription factors, and GTPase associated proteins. A series of secondary
assays confirmed the relevance of the primary screen hits to insulin signaling and provided further insight into their modes
of action.
Conclusion/Significance: Among the novel hits was PALD (KIAA1274, paladin), a previously uncharacterized protein that
when overexpressed led to inhibition of insulin’s ability to down regulate a FOXO1A-driven reporter gene, reduced
upstream insulin-stimulated AKT phosphorylation, and decreased insulin receptor (IR) abundance. Conversely, knockdown
of PALD gene expression resulted in increased IR abundance, enhanced insulin-stimulated AKT phosphorylation, and an
improvement in insulin’s ability to suppress FOXO1A-driven reporter gene activity. The present data demonstrate that the
application of arrayed genome-wide screening technologies to insulin signaling is fruitful and is likely to reveal novel drug
targets for insulin resistance and the metabolic syndrome.
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Introduction
Approximately 143 million people worldwide are afflicted by
type 2 diabetes (T2D). Clinical and experimental data have
demonstrated that T2D is highly correlated with the induction of
insulin resistance. Finding negative modulators of insulin signaling
is therefore of enormous scientific and therapeutic importance.
Insulin activates two major signaling pathways, namely the
phosphatidylinositol-3-OH kinase (PI(3)K)-AKT and RAS-MAPK
pathways [1]. While the RAS-MAPK pathway regulates cell
growth, PI(3)K-AKT signaling is thought to be the key pathway by
which insulin controls metabolic processes. Several insulin
signaling inhibitors (e.g. PTP1B, PTEN, and IKKb) have already
been found [2–5]. Given the complexity of insulin signaling, many
more are likely to be discovered. For example, TRB3, a CDC25
binding protein homolog, has recently been reported to down-
regulate hepatic AKT activation by insulin [6].
In the liver, insulin down regulates glucose production in part
by repressing the transcription of the glucose-6-phosphatase
(G6Pase) gene via a well-documented PI(3)K-AKT-FOXO1A
phosphorylation cascade [7]. Taking advantage of recent advances
in functional profiling technology, we initiated a cDNA screen
using the promoter of the G6Pase catalytic subunit driving
luciferase expression as an insulin responsive reporter (G6Pase-
Luc), with the objective of finding negative modulators of insulin
signaling. In this report we describe the identification and initial
functional characterization of novel cDNA inhibitors of insulin
signaling, especially the potential regulatory role of the previously
uncharacterized protein PALD on IR signaling.
Results
We hypothesized that forced expression of a negative modulator of
insulinsignaling wouldde-repressG6Pase-Lucreporteractivityinthe
presence of insulin (Figure 1A). The screen was optimized in readily
transfectable Chinese Hamster Ovary (CHO-K1) cells, which are
responsive to insulin stimulation as demonstrated by the induction of
AKT phosphorylation (Figure S1A). In addition, CHO-K1 cells
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G6Pase-Luc is inactive in these cells without exogenous expression of
FOXO1A (Figure S1B and C). Subsequently, co-transfection of
FOXO1A with a genome-scale collection of 18,441 purported full
length human cDNAs was performed, yielding 16,581 usable data
points and 161 hits with reporter activities greater than two standard
deviations above the mean (Figure 1B).
We chose 71 primary screen hits for detailed follow-up based on
assay activity (i.e., generally favored those hits with highest primary
screen activity, although several novel hits with lesser activities still
above the two standard deviation cut-off were also included), novelty
(i.e., included those hits for which little or no functional information
has previously been reported), and predicted functions (i.e., included
hits with predicted signal transduction functions such as kinases,
phosphatases, and adaptors, while with a few exceptions excluding
transcription factor-related hits since these would be predicted to
have a higher ‘‘nonspecific’’ hit rate in our screen). First, to determine
whether activation of the reporter by the hits was specifically due to
inhibition of insulin signaling, we repeated the G6Pase-Luc reporter
assay with and without insulin and normalized the reporter activity in
the presence of insulin to that in the absence of insulin (Figure 2A).
The resulting ratio is directly correlated with the extent of insulin
inhibition. For example, whereas overexpression of a negative control
a-tubulin (K-a-1) resulted in a minimal ratio of 0.15 (luciferase
activity in the presence of insulin is 15% of that in the absence of
insulin), expression of PTEN and GRB10, both known inhibitors of
insulin signaling, yielded more than two-fold higher inhibition ratios
of0.35and 0.7respectively(Figure 2A).Statistically,ofthe71cDNAs
examined, 46 significantly overcame insulin’s repression of G6Pase
promoter activity compared to the negative control,K-a-1(Figure2A
and Table S1). Importantly, dual specificity phosphatase (DUSP)
family members identified in the original screen (DUSP1, 4, 5, 6, 7,
and 10) were positive in the insulin-dependency test, while other
DUSP family members (DUSP2, 3, & 14) were negative in both the
primary and initial secondary screening, indicating specificity among
DUSP family members in their effects on insulin signaling and
excluding generalized phosphatase overexpression as a source of
experimental artifacts.
To obtain initial mechanistic insights we next sought to place
secondary hits in the context of two major components of insulin
signaling, FOXO1A and AKT. To examine reliance upon
FOXO1A, we used a FOXO1A-dependent reporter (IRE-4U)
containing four copies of the FOXO1A binding motifs from the
G6Pase promoter [8] to analyze the effect of the 46 insulin signaling
inhibitorsonreporteractivityinthepresence andabsenceofinsulin.
As observed with the G6Pase-Luc reporter assay, PTEN (0.60) and
GRB10 (0.99) exhibited at least two-fold greater insulin inhibition
ratios than the K-a-1 control (0.26) in the context of the IRE-4U
reporter assay. 34 of the 46 insulin-dependent cDNAs also
significantly inhibited insulin signaling on the FOXO1A-dependent
reporter as compared to K-a-1 (Figure 2B and Table S2) indicating
that they act at or upstream of FOXO1A.
Since insulin regulates FOXO1A transcriptional activity predom-
inately through AKT [9], the effect of overexpression of screen hits on
insulin-induced AKT phosphorylation was investigated at six time
points over a 24 hour period using a high throughput multiplex
immunoassay that detects total AKT and phosphoAKT (S473)
proteins simultaneously. Illustrated in Figure 3A are representative
data from a single time point 8.5 hours after insulin stimulation (see
Table S3 and Figure S2 for the complete data set). For each cDNA, the
raw signal of pAKT was first normalized to the raw signal of total AKT
(pAKT/total AKT). The fold repression of the insulin response was
then calculated by dividing (pAKT/total AKT) for the control (vector
only) by (pAKT/total AKT) for a given cDNA. Consistent with
previous reports demonstrating their ability to modulate insulin
signaling when overexpressed [10–12], GRB10, PTEN, PIK3R1,
and PIK3R2 inhibited insulin-induced AKT phosphorylation 3.7-,
4.2-, 5.4-, and 4.8-fold respectively. In Figure 3B are representative
time course data for two of the novel screen hits, ABR and PALD,
displayed as the raw signal of pAKT normalized to the raw signal of
total AKT. Overexpression of ABR or PALD clearly inhibited insulin-
stimulated AKT phosphorylation at all time points tested (Figure 3B).
Based on the data in Figures 3A, 3B, and the complete time course
(Supplemental Information, Table S3 and Figure S2), we found that
A B R ,D O K 2 ,N C K 2 ,P A L D ,P T P R A ,R P S 6 K A 2 ,S A S H 1 ,a n d
WBP2 significantly inhibited insulin-stimulated AKT phosphorylation
at all time points compared to the vector control.
Among the novel hits shown to affect AKT phosphorylation, we
elected to further dissect the potential insulin signaling regulatory
role of the previously uncharacterized protein PALD (KIAA1274,
paladin). First, we confirmed the high throughput immunoassay
results by examining AKT phosphorylation at S473 by Western
blotting, as well as extending the analysis to the AKT T308 site
(Figure 4A). PALD overexpression resulted in diminished insulin-
stimulated AKT phosphorylation at both S473 and T308 at all
time points tested (Figure 4A).
To further establish the biological relevance of PALD in insulin
signaling, we performed PALD knockdown in rat liver H4IIE cells
containing an integrated G6Pase-Luc reporter (H4IIE-G6Pase,
Figure 4B). One of the two siRNAs (rPALD2) that were tested
effectively knocked down rPALD mRNA expression levels (,80%,
Figure 4B inset) and, as expected, increased insulin sensitivity
measured by reporter activity. To further investigate the
relationship between PALD expression and insulin-simulated
AKT phosphorylation and to expand the range of insulin-
responsive cell lines tested, we electroporated the mouse myoblast
C2C12 cell line with a mPALD siRNA Smartpool (an equimolar
pool of 4 individual siRNAs), and separately with two individual
siRNAs from the pool, achieving 60–70% reduction of mPALD
mRNA levels and increasing insulin-induced AKT phosphoryla-
tion at both S473 and T308 (Figure 4C). These results, obtained in
multiple cellular contexts using both reporter activation and AKT
phosphorylation status, strongly suggest a role for PALD in
insulin-induced AKT phosphorylation.
Because overexpression of PALD resulted in the inhibition of
both S473 and T308 phosphorylation on AKT, we hypothesized
that PALD could be targeting an upstream component in the
insulin signaling pathway, including the insulin receptor (IR). We
stripped the membrane used in Figure 4A and re-probed with an
anti-insulin receptor b subunit antibody and a phosphotyrosine-
specific antibody targeting Y1162/Y1163 of IR. Forced expression
of PALD yielded a reduction of phosphorylated Y1162/Y1163
that correlated with a decreased overall abundance of the mature
IR b subunit (Figure 4D), with both bands exhibiting a faster
migration on the gel. These observations are unlikely due to
inconsistent loading, since the level of total AKT is fairly constant
(Figure 4A). Moreover, PALD-mediated down regulation of IR
was likely not simply an artifact of overexpression since PALD
depletion by siRNA enhanced IR abundance and Y1162/Y1163
phosphorylation levels with a corresponding augmentation in
insulin-induced AKT activation (i.e., T308 phosphorylation,
Figure 4E). Together these results implicate a role for PALD as
a negative regulator of insulin signaling.
Discussion
In the present study, we successfully integrated an arrayed
cDNA functional profiling platform with an insulin responsive
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PLoS ONE | www.plosone.org 2 September 2009 | Volume 4 | Issue 9 | e6871Figure 1. Genome-wide screen for negative modulators of insulin signaling. (A) Scheme illustrating screen design. The G6Pase-Luc reporter
is activated by FOXO1A transcription factor and cAMP treatment in the absence of insulin. Upon treatment of cells with insulin, a phosphorylation
cascade is induced that leads to inactivation of FOXO1A and repression of G6Pase-Luc activity. In the presence of a cDNA-encoded inhibitor of insulin
signaling however, G6Pase-Luc activity is restored. (B) Single-well luminescent signals of the 16,581 high-quality cDNA data set obtained from
screening an arrayed library encoding 18,441 human transcripts. The luminescent signal is plotted on the y-axis as relative light units (RLU) with the
corresponding well number on the x-axis. Representative hits are labeled in red and denoted as gene symbol plus transcript variant number, as
applicable, and include: PTEN, PIK3R2, GRB10, PEA15, NCK2, ABR v1, SASH1, KIAA1274 (PALD), DUSP1, DUSP6 v1, DUSP7, DUSP10 v1, PTPRE v1, and
PTPRR v2.
doi:10.1371/journal.pone.0006871.g001
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PLoS ONE | www.plosone.org 3 September 2009 | Volume 4 | Issue 9 | e6871Figure 2. Characterization of hits from the primary screen. (A) Inhibition of insulin’s repression of the G6Pase-Luc reporter. Seventy-one
selected hits were retested in the primary assay in the presence and absence of insulin. Inhibition of insulin response was defined as the ratio of
luciferase activity in the presence of insulin to that in the absence of insulin, which is positively correlated with the extent of inhibition of the insulin
signal. The cDNAs were filtered based on their ability to significantly (p,0.05) inhibit insulin signaling in an insulin-dependent manner relative to the
negative control, a-tubulin (K-a-1). (B) Inhibition of insulin effect on IRE-4U reporter. The 46 cDNAs demonstrated to inhibit insulin signaling were
assayed with a FOXO1A-dependent promoter (IRE-4U). Similar to (A) above, the IRE-4U luciferase activity in the presence of insulin was divided by
that in the absence of insulin. This ratio is positively correlated with the extent of inhibition of FOXO1A-dependent transcription by insulin. Hits acting
at or upstream of FOXO1A were those that had a ratio greater than that of the negative control, K-a-1 at p,0.05.
doi:10.1371/journal.pone.0006871.g002
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PLoS ONE | www.plosone.org 4 September 2009 | Volume 4 | Issue 9 | e6871reporter that targeted the FOXO1A pathway to search for novel
negative modulators of insulin signaling. Although the screen was
biased toward a particular arm of the insulin signaling pathway,
we identified proteins that act upstream in the pathway. In
particular, we found that PALD inhibits insulin-stimulated AKT
phosphorylation and this correlates with a decrease in IR
abundance.
PALD (KIAA1274) was identified in large-scale cDNA
sequencing efforts [13]. As such, relatively little is known about
its function. The cDNA encodes a protein of 856 amino acids with
two phosphatase signature motifs (CXXGXGR) and an N-
terminal myristoylation site. The regions containing the phospha-
tase signature motifs are related to one another, but are only
distantly related to the protein tyrosine phosphatase family [14].
The protein exhibits 41% amino acid identity across vertebrate
species (data not shown). EST (www.ncbi.nlm.nih.gov/UniGene)
and gene expression (biogps.gnf.org) databases show that it is
expressed tissue specifically, with highest expression in lung and
Figure 3. Inhibition of insulin-stimulated Akt phosphorylation by screen hits. (A) Selected screen hits that inhibit insulin signaling at or
upstream of FOXO1A were assayed across an insulin treatment time course for their ability to inhibit insulin-induced AKT phosphorylation using a
multiplex immunoassay that simultaneously measures phospho-(Ser473) and total AKT levels. Shown here are representative data from a single time
point, 8.5 hours post insulin treatment. For the complete time-course data set see Table S3 and Figure S2. (B) Complete time-course data for
inhibition of insulin-stimulated AKT phosphorylation by ABR and PALD. For comparison purposes, shown here are the insulin treatment time-course
results for two of the novel insulin signaling hits, ABR and PALD, relative to well-known inhibitors, GRB10 and PTEN, and vector control. The individual
microplate data shown here are displayed as the pAKT/tAKT ratio on the y-axis with the insulin-treatment time-points denoted on the x-axis. For
additional data sets, see Table S3 and Figure S2.
doi:10.1371/journal.pone.0006871.g003
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PLoS ONE | www.plosone.org 5 September 2009 | Volume 4 | Issue 9 | e6871Figure 4. PALD overexpression inhibits insulin–induced AKT phosphorylation while PALD knockdown improves insulin response
and enhances insulin-induced AKT phosphorylation. (A) COS7 cells transfected with empty vector or human PALD were serum starved prior
to treatment with 50 nM insulin for the times indicated and analyzed for AKT phosphorylation (Ser473 and Thr308) and total AKT expression by
Western blotting. (B) H4IIE rat liver cells containing an integrated G6Pase-Luc reporter were electroporated with control siRNA or siRNAs against rat
PALD. The extent of PALD mRNA knockdown was measured by qPCR 72 hours after transfection (inset) and inhibition of the luciferase activity in
serum-starved cells by insulin (fold repression) was determined. *P,0.01, compared with control siRNA. (C) mPALD knockdown enhances insulin-
induced AKT phosphorylation. C2C12 mouse myoblast cells were transfected with control siRNA, pooled mPALD siRNA (mPALD siRNA00), or the
individual mPALD siRNAs (mPALD siRNA01 and mPALD siRNA02), serum starved overnight, and treated with insulin for the indicated times before
PALD mRNA was measured by qPCR (lower panel) and AKT phosphorylation was analyzed by Western blotting (upper panel). (D) The COS7 cells
transfected in (A) were also analyzed for insulin receptor (IR) phosphorylation and IR b subunit expression by Western blotting. (E) mPALD
knockdown enhances insulin-stimulated IR phosphorylation and increases IR abundance. C2C12 cells transfected with control siRNA or mPALD
siRNA01 were serum starved overnight, treated with 1 nM insulin, and analyzed for phospho IR and total IR by Western blotting. Phospho AKT was
included as a control for insulin action and total AKT was included as a loading control.
doi:10.1371/journal.pone.0006871.g004
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embryonic tissue and in C2C12 cells. The human protein atlas
(proteinatlas.org) shows a wider expression pattern with three
different forms of the protein visible by western blot [15]. It is
therefore tempting to speculate that PALD influences insulin
signaling by dephosphorylating IR upon insulin-mediated autop-
hosphorylation, leading to IR turnover. To date, however, we
have been unable to detect phosphatase activity with full-length or
truncated expression forms of PALD (data not shown) and so the
precise mechanism by which PALD modulates IR abundance
remains to be determined. Nevertheless, to our knowledge, this is
the first functional characterization of PALD in insulin signaling or
any other pathway. Pald mouse knockouts, which are being
generated, should further clarify PALD’s role and necessity in
mediating insulin signaling.
Other primary screen hits represent a diverse array of
biochemical functions and include many known inhibitors of
insulin signaling, such as phosphatase and tensin homolog (PTEN),
which has been shown to negatively modulate insulin signaling by
both gain-of-function and loss-of-function studies [4,5], PI(3)K p85
b subunit (PIK3R2), whose concentration is critical in regulating
PI(3)K activity [12,16], and phosphoprotein enriched in astrocytes
15 (PEA15), which is up-regulated in type 2 diabetes and whose
transgenic expression causes diabetes by affecting both insulin
sensitivity and insulin secretion [17,18]. The identification of these
well-characterized insulin signaling modulators as well as a
number of additional hits previously linked to this pathway not
only served as effective internal positive controls but also support
the premise of our primary screening approach.
Whereas the primary assay merely identified known and novel
inhibitors of insulin signaling, we applied a series of secondary
assays in order to shed further light on the role such inhibitors may
play. NCK2 for example, was previously implicated in insulin
signaling due to its interaction with insulin receptor substrate-1
(IRS-1) [19]. Here we found that NCK2 inhibits insulin signaling
and does so by repressing insulin-induced AKT phosphorylation.
DOK2 has also been implicated in insulin signaling by virtue of its
similarity to IRS family members [20]; we now provide functional
evidence for a role for DOK2 as an inhibitor of insulin action.
Members of two distinct phosphatase families, the receptor type
protein tyrosine phosphatase (PTPR) family (e.g. PTPRE and
PTPRA) and the dual specificity phosphatase (DUSP) family (e.g.
DUSP1, 4, 6, 7, and 10, these are also known as MAP kinase
phosphatases, MKPs), were prominent among our hits and certain
family members have previously been implicated in insulin
signaling. Notably, in addition to DUSP6 (MKP3) and DUSP7
(MKPX), which were previously shown to overcome insulin’s
repression of the PEPCK promoter via an unknown mechanism
[21,22], we identified DUSP1 (MKP1), DUSP4 (MKP2), and
DUSP10 (MKP5) as potential inhibitors of insulin signaling. We
also further demonstrated that some of these phosphatases (DUSP
1, 4, 7, 10, PTPRE v2, and PTPRR v2) affect insulin-regulated
FOXO1A activity without inhibiting AKT phosphorylation. The
fact that several of the DUSPs inhibited insulin regulated
FOXO1A activity independent of AKT phosphorylation at S473
(Figure 2B and 3A) indicates that the MAPK pathway plays a role
in regulating FOXO1A activity. Such a role has recently been
demonstrated for ERK and p38MAPK, which phosphorylate
FOXO1 at sites distinct from those phosphorylated by AKT [23].
Phosphorylation of FOXO1 at the ERK sites promotes its
interaction with the transcription factor ETS and potentiates
ETS’s ability to activate transcription [23].
In addition to PALD, a number of the confirmed screen hits
have not previously been implicated in insulin signaling and are
therefore putative novel inhibitors of insulin signaling. For
example, active BCR related gene (ABR), a GTPase associated
protein that exhibits intrinsic GAP and GEF activities, was
previously demonstrated to participate in postnatal cerebellar
development [24]. ABR overexpression potently inhibited insulin’s
effect on FOXO1A-mediated transcription and AKT phosphor-
ylation (Figure 2B and 3A). Although sharing 68% amino acid
sequence identity to ABR [25,26], BCR overexpression had only a
minor inhibitory effect on insulin-induced AKT phosphorylation
(data not shown). It has recently been reported that both BCR and
ABR are GAPs for Rac and loss of either ABR or BCR leads to
abnormal macrophage morphology and motility [27]. Consistent-
ly, we find that overexpression of exogenous ABR leads to cells
with fewer protrusions (data not shown) and this many explain in
part its effects on insulin signaling.
Another noteworthy hit not previously linked to insulin
signaling was the adaptor SAM and SH3 domain containing 1
(SASH1). Recent work has led to the prediction that SASH1 may
function as a tumor suppressor and play a significant role in breast
cancer and lung cancer [28]. Our studies showed that SASH1 can
also significantly inhibit insulin’s ability to repress FOXO1A-
mediated transcription by inhibiting insulin-induced AKT phos-
phorylation (Figure 2B and 3A). Since insulin signaling via the
PI(3)K-AKT pathway also plays a role in cell proliferation, our
results may have pinpointed the mechanism by which SASH1
regulates cell proliferation.
Although the overall biological significance of our screen results
will require further studies for each individual hit, the combination
of different pathway assays we employed for initial follow-up has
already provided significant preliminary validation and revealed
interesting mechanistic leads for many of the screen hits. In
conclusion, the present data strongly illustrate the applicability of
arrayed genome-wide screening technologies to identifying novel
modulators of insulin signaling.
Materials and Methods
Materials
Anti-phospho-insulin receptor (Tyr 1162/1163) antibody was
purchased from Calbiochem (San Diego, CA). Anti-insulin
receptor b subunit antibodies were acquired from Santa Cruz
Biotechnology Inc. (Santa Cruz, CA) and BD Transduction
Laboratories (San Diego, CA). Affinity purified antibodies against
total AKT and phosphorylated AKTs (Thr 308 and Ser 473) were
obtained from Cell Signaling Technology Inc. (Beverly, MA).
Anti-flag antibody was obtained from Sigma (St. Louis, MO). The
OriGene TrueClone Collection of human full-length cDNA clones
was purchased from OriGene Technologies (Rockville, MD). For
rat PALD knockdown studies, Negative Control siRNA Alexa
Fluor 546 (59-TTCTCCGAACGTGTCACGT-39), rPALD-1 (59-
GCAGCCCACCTACAGATAT-39), and rPALD-2 (59-
CCTCTTTAATGCCTACCTT-39) were purchased from Qia-
gen (Valencia, CA). For mouse PALD knockdown studies, the
following siRNAs were purchased from Dharmacon: siCON-
TROL Non-Targeting siRNA #1( 5 9-TAGCGACTAAACA-
CATCAA-39), mPALD SMARTpool, mPALD-01 (59-
GGCCTTACCTACTGCCGTA-39), and mPALD-02 (59-GA-
GATAATGTGTACCACGT-39).
Constructs
The G6Pase-Luc reporter was constructed by cloning a
,1.7 kbp fragment (21631R+25) of the 59-UTR of the human
G6Pase catalytic subunit into the pGL3-Basic Vector (Promega,
Madison, WI). The IRE-4U pGL3 reporter was constructed by
Insulin Signaling Inhibitors
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contains three FOXO binding motifs, from the human G6P
catalytic subunit 59-UTR (2185R2157).
High-Throughput cDNA screen
An arrayed library of 18,441 human full-length cDNAs from the
OriGene TrueClone Collection was screened by high-throughput
reverse transfection of Chinese Hamster Ovary (CHO-K1) cells.
Briefly, transfection mixture containing Opti-MEM I (Invitrogen,
Carlsbad, CA), G6Pase-Luc reporter (2 ng/well), human
FOXO1A (50 ng/well), and FuGENE 6 (Roche, Indianapolis,
IN) was dispensed into 384-well plates pre-spotted with individual
cDNAs (,40 ng/well) and incubated at room temperature for
1 hour. CHO-K1 cells, cultured in DMEM/F12 supplemented
with 10% FBS and penicillin/streptomycin, were then added
(11,000 cells/well) and the 384-well plates were incubated
overnight at 37uC, 5% CO2. Subsequently, cells were starved in
serum-free DMEM/F12 for 8 hours prior to treatment with a
mixture containing 500 nM human recombinant insulin (Sigma-
Aldrich, St. Louis, MO) and 2 mM dibutyryl-cAMP (Roche,
Indianapolis, IN). Approximately 24 hours after treatment, Bright-
Glo Reagent (Promega, Madison, WI) was added to each well and
luminescence readings were acquired using an Acquest microplate
reader (Molecular Devices, Sunnyvale, CA). Follow-up assays with
and without insulin were performed similarly except that a
conventional FuGENE 6-mediated forward transfection protocol
(cells first) was followed using either the G6Pase-Luc reporter or
IRE-4U reporter.
Phospho (Ser473)/Total AKT Multiplex Immunoassay
Phospho (Ser 473) and total AKT levels in cell lysates following
transient transfection of selected screen hits were measured using
the MSD MULTI-SPOT Assay System (Meso Scale Discovery,
Gaithersburg, MD). Briefly, 96-well plates pre-seeded with COS7
cells to be ,80% confluent were transfected with selected cDNAs
(150 ng/well) using the TransIT-COS Transfection Kit (Mirus,
Madison, WI). The transfected COS7 cells were cultured in
DMEM supplemented with 10% heat-inactivated FBS at 37uC
and 5% CO2 for 16–24 hours prior to replacing the growth
medium with serum-free DMEM. At various time-points following
a minimum of 6 hours in serum-free conditions, selected wells
were treated with human recombinant insulin (50 nM final
concentration). At the end of the time-course, approximately
20–32 hours following initiation of the serum-free incubation step,
cell lysates were prepared on ice using MSD Complete Lysis
Buffer. Cell lysates were transferred to pre-blocked MSD MULTI-
SPOT 96-well plates and incubated with shaking for 1–2 hours at
room temperature, washed several times, incubated with MSD
SULFO-TAG Detection Antibody with shaking for an additional
1-2 hours at room temperature, washed several times, and
analyzed in MSD Read Buffer T using an MSD Sector Imager
6000. Fold-repression of insulin-induced AKT phosphorylation for
each of the assayed screen hits was determined by calculating the
ratio of phospho AKT to total AKT (pAKT/tAKT) for the vector
control, pCMV6-XL5, and dividing it by the pAKT/tAKT ratio
obtained for each individual cDNA.
Quantitative PCR
Quantitative PCR reactions were performed using the Super-
Script III Platinum One-Step qRT-PCR Kit (Invitrogen, Carls-
bad, CA) and an ABI PRISM 7900HT Sequence Detection
System (Applied Biosystems, Foster, CA) according to manufac-
turer’s protocol. The qPCR probe and primers sequences for rat
PALD were as follows: probe, 59-TGCCTGTGCAGAGTTA-
CATGACCT-39; forward primer, 59-GAGGTGGATCGAGC-
CATCA-39; reverse primer 59- TGGTTTTTGAG-
GAGCTCTTCCT-39. The qPCR probe and primers sequences
for mouse PALD were as follows: probe, 59-
TGCGGCGTTGGACATTGTC-39; forward primer, 59-
GCCACCACGTGAAGAAGGA-39; reverse primer 59-
GAAGGTGGTAGTGCATAGGTGTCA-39.
siRNA Transfection
300 pmoles of siRNAs targeting mouse PALD or rat PALD
were electroporated into 2610
6 C2C12 or H4IIE cells using an
Amaxa Nucleofector system (Amaxa, Gaithersburg, MD) accord-
ing to manufacturer’s protocol. Cells were subsequently cultured
for 48–72 hours before insulin stimulation and harvesting the cells
for downstream applications.
Western Blot Analysis
Briefly, proteins were extracted from transfected COS7 cells
(prepared as detailed above) using MSD Complete Lysis Buffer
(Meso Scale Discovery, Gaithersburg, MD) or from electroporated
C2C12 cells using Triton X lysis buffer comprising 50 mM Tris-
HCl, pH 7.5, 100 mM NaCl, 1% Triton X-100, 10% glycerol,
1 mM EDTA, and 0.1 mg/ml Calyculin A (Cell Signaling
Technology, Beverly, MA), and protease inhibitor and phospha-
tase inhibitor cocktails (Sigma-Aldrich, St. Louis, MO). Total
cellular proteins were separated by 10% or 8% Tris-glycine SDS/
PAGE (Invitrogen, Carlsbad, CA) and transferred to nitrocellulose
membranes. Proteins were detected with primary antibodies and
horseradish peroxidase-conjugated secondary antibodies by using
the ECL-Plus kit (GE Healthcare, United Kingdom).
Supporting Information
Figure S1 CHO-K1 cells are responsive to insulin stimulation
and express an insignificant amount of endogenous FOXO1A
transcription factor. (a) CHO-K1 cells were treated with 100 nM
insulin for the times indicated and analyzed for AKT phosphor-
ylation and total IR expression by western blot. (b) Expression
level of FOXO1A in CHO-K1 cells. Human FOXO1A cDNA
and the vector control were transfected into CHO-K1 cells and
allowed to express for 48 hours. Cell extracts were taken and
analyzed by Western blotting using anti-FKHR (Cell Signaling
Technology, Beverly, MA) as primary antibody. (c) G6Pase-Luc
reporter is inactive in CHO-K1 cells without exogenous
expression of FOXO1A. CHO-K1 cells were co-transfected with
2 ng or 5 ng of G6Pase-Luc and 50 ng or 75 ng of a-tubulin
(negative control) or FOXO1A. Insulin and cAMP stimulations
were performed as described in Methods.
Found at: doi:10.1371/journal.pone.0006871.s001 (0.07 MB
PDF)
Figure S2 Phospho-(Ser473)/Total AKT Multiplex Immunoas-
say Results. As detailed in the legend for Table S3, up to three
independent experiments were carried out for each cDNA whose
pAKT and tAKT levels were simultaneously measured as detailed
in the Methods. For comparative purposes, the computed average
pAKT/tAKT ratios 6 the standard deviations for the indicated
time-points from each independent experiment performed on an
individual cDNA (in yellow; listed in alphabetical order) are
plotted relative to the corresponding microplate values obtained
with the negative vector control, pCMV6-XL5 (in red), and the
positive control, Grb10 (in blue). n.d., not determined.
Found at: doi:10.1371/journal.pone.0006871.s002 (0.69 MB
PDF)
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PLoS ONE | www.plosone.org 8 September 2009 | Volume 4 | Issue 9 | e6871Table S1 Summary of the first cell-based follow-up assay. Data
obtained and analyzed as described in figure 2a.
Found at: doi:10.1371/journal.pone.0006871.s003 (0.07 MB
PDF)
Table S2 Summary of the second cell-based follow-up assay.
Data obtained and analyzed as described in figure 2b.
Found at: doi:10.1371/journal.pone.0006871.s004 (0.05 MB
PDF)
Table S3 Phospho-(Ser473)/Total AKT Multiplex Immunoas-
say Data. Shown here are the raw pAKT and tAKT data sets as
well as the calculated pAKT/tAKT ratios for each of the selected
screen hits (listed in alphabetical order) that were assayed as
detailed in the Methods. The four independent experiments that
were performed are color-coded with additional specific time-
course differences indicated in the table heading. The ‘‘0’’ time-
point corresponds to no insulin treatment while the insulin
(50 nM) treatment times are indicated in minutes (m) and hours
(h). Generally, for each time- point examined two or three
replicates were performed per experiment and up to three
independent experiments were carried out for each assayed
cDNA. For comparative purposes, the computed average
pAKT/tAKT ratios 6 the standard deviations for the indicated
time-points from each independent experiment performed on an
individual cDNA are plotted in Figure S2 relative to the
corresponding microplate values obtained with the negative vector
control, pCMV6-XL5, and the positive control, Grb10.
Found at: doi:10.1371/journal.pone.0006871.s005 (0.05 MB
PDF)
Acknowledgments
We are grateful for the technical assistance of the following people: Joe
Quinto, Sandy Bohan, Richard Savary, Paul DeJesus, Myleen Medina,
Barrett Clement, Brendan Smith, and Cynthia Cienfuegos.
Author Contributions
Conceived and designed the experiments: SMAH MKH JLP APO NG.
Performed the experiments: SMAH MKH JLP. Analyzed the data: SMAH
MKH JLP APO NG. Contributed reagents/materials/analysis tools: APO
NG. Wrote the paper: SMAH MKH JLP APO NG.
References
1. White MF (2003) Insulin signaling in health and disease. Science 302:
1710–1711.
2. Arkan MC, Hevener AL, Greten FR, Maeda S, Li ZW, et al. (2005) IKK-beta
links inflammation to obesity-induced insulin resistance. Nat Med 11: 191–198.
3. Elchebly M, Payette P, Michaliszyn E, Cromlish W, Collins S, et al. (1999)
Increased insulin sensitivity and obesity resistance in mice lacking the protein
tyrosine phosphatase-1B gene. Science 283: 1544–1548.
4. Kurlawalla-Martinez C, Stiles B, Wang Y, Devaskar SU, Kahn BB, et al. (2005)
Insulin hypersensitivity and resistance to streptozotocin-induced diabetes in mice
lacking PTEN in adipose tissue. Mol Cell Biol 25: 2498–2510.
5. Stiles B, Wang Y, Stahl A, Bassilian S, Lee WP, et al. (2004) Liver-specific
deletion of negative regulator Pten results in fatty liver and insulin
hypersensitivity [corrected]. Proc Natl Acad Sci U S A 101: 2082–2087.
6. Du K, Herzig S, Kulkarni RN, Montminy M (2003) TRB3: a tribbles homolog
that inhibits Akt/PKB activation by insulin in liver. Science 300: 1574–1577.
7. Schmoll D, Walker KS, Alessi DR, Grempler R, Burchell A, et al. (2000)
Regulation of glucose-6-phosphatase gene expression by protein kinase Balpha
and the forkhead transcription factor FKHR. Evidence for insulin response unit-
dependent and -independent effects of insulin on promoter activity. J Biol Chem
275: 36324–36333.
8. Vander Kooi BT, Streeper RS, Svitek CA, Oeser JK, Powell DR, et al. (2003)
The three insulin response sequences in the glucose-6-phosphatase catalytic
subunit gene promoter are functionally distinct. J Biol Chem 278: 11782–11793.
9. Barthel A, Schmoll D, Unterman TG (2005) FoxO proteins in insulin action and
metabolism. Trends Endocrinol Metab 16: 183–189.
10. Wick KR, Werner ED, Langlais P, Ramos FJ, Dong LQ, et al. (2003) Grb10
inhibits insulin-stimulated insulin receptor substrate (IRS)-phosphatidylinositol
3-kinase/Akt signaling pathway by disrupting the association of IRS-1/IRS-2
with the insulin receptor. J Biol Chem 278: 8460–8467.
11. Ono H, Katagiri H, Funaki M, Anai M, Inukai K, et al. (2001) Regulation of
phosphoinositide metabolism, Akt phosphorylation, and glucose transport by
PTEN (phosphatase and tensin homolog deleted on chromosome 10) in 3T3-L1
adipocytes. Mol Endocrinol 15: 1411–1422.
12. Brachmann SM, Ueki K, Engelman JA, Kahn RC, Cantley LC (2005)
Phosphoinositide 3-kinase catalytic subunit deletion and regulatory subunit
deletion have opposite effects on insulin sensitivity in mice. Mol Cell Biol 25:
1596–1607.
13. Nagase T, Ishikawa K, Kikuno R, Hirosawa M, Nomura N, et al. (1999)
Prediction of the coding sequences of unidentified human genes. XV. The
complete sequences of 100 new cDNA clones from brain which code for large
proteins in vitro. DNA Res 6: 337–345.
14. Alonso A, Sasin J, Bottini N, Friedberg I, Osterman A, et al. (2004) Protein
tyrosine phosphatases in the human genome. Cell 117: 699–711.
15. Berglund L, Bjorling E, Oksvold P, Fagerberg L, Asplund A, et al. (2008) A
genecentric Human Protein Atlas for expression profiles based on antibodies.
Mol Cell Proteomics 7: 2019–2027.
16. Ueki K, Yballe CM, Brachmann SM, Vicent D, Watt JM, et al. (2002) Increased
insulin sensitivity in mice lacking p85beta subunit of phosphoinositide 3-kinase.
Proc Natl Acad Sci U S A 99: 419–424.
17. Condorelli G, Vigliotta G, Iavarone C, Caruso M, Tocchetti CG, et al. (1998)
PED/PEA-15 gene controls glucose transport and is overexpressed in type 2
diabetes mellitus. Embo J 17: 3858–3866.
18. Vigliotta G, Miele C, Santopietro S, Portella G, Perfetti A, et al. (2004)
Overexpression of the ped/pea-15 gene causes diabetes by impairing glucose-
stimulated insulin secretion in addition to insulin action. Mol Cell Biol 24:
5005–5015.
19. Tu Y, Liang L, Frank SJ, Wu C (2001) Src homology 3 domain-dependent
interaction of Nck-2 with insulin receptor substrate-1. Biochem J 354: 315–322.
20. Cai D, Dhe-Paganon S, Melendez PA, Lee J, Shoelson SE (2003) Two new
substrates in insulin signaling, IRS5/DOK4 and IRS6/DOK5. J Biol Chem
278: 25323–25330.
21. Xu H, Yang Q, Shen M, Huang X, Dembski M, et al. (2005) Dual specificity
MAP kinase phosphatase 3 activates PEPCK transcription and increases
gluconeogenesis in rat hepatoma cells. J Biol Chem.
22. Xu H, Dembski M, Yang Q, Yang D, Moriarty A, et al. (2003) Dual specificity
mitogen-activated protein (MAP) kinase phosphatase-4 plays a potential role in
insulin resistance. J Biol Chem 278: 30187–30192.
23. Asada S, Daitoku H, Matsuzaki H, Saito T, Sudo T, et al. (2007) Mitogen-
activated protein kinases, Erk and p38, phosphorylate and regulate Foxo1. Cell
Signal 19: 519–527.
24. Kaartinen V, Gonzalez-Gomez I, Voncken JW, Haataja L, Faure E, et al. (2001)
Abnormal function of astroglia lacking Abr and Bcr RacGAPs. Development
128: 4217–4227.
25. Tan EC, Leung T, Manser E, Lim L (1993) The human active breakpoint
cluster region-related gene encodes a brain protein with homology to guanine
nucleotide exchange proteins and GTPase-activating proteins. J Biol Chem 268:
27291–27298.
26. Chuang TH, Xu X, Kaartinen V, Heisterkamp N, Groffen J, et al. (1995) Abr
and Bcr are multifunctional regulators of the Rho GTP-binding protein family.
Proc Natl Acad Sci U S A 92: 10282–10286.
27. Cho YJ, Cunnick JM, Yi SJ, Kaartinen V, Groffen J, et al. (2007) Abr and Bcr,
two homologous Rac GTPase-activating proteins, control multiple cellular
functions of murine macrophages. Mol Cell Biol 27: 899–911.
28. Zeller C, Hinzmann B, Seitz S, Prokoph H, Burkhard-Goettges E, et al. (2003)
SASH1: a candidate tumor suppressor gene on chromosome 6q24.3 is
downregulated in breast cancer. Oncogene 22: 2972–2983.
Insulin Signaling Inhibitors
PLoS ONE | www.plosone.org 9 September 2009 | Volume 4 | Issue 9 | e6871